CD117 (c-Kit) Monoclonal Antibody (ACK2), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: The ACK2 monoclonal antibody reacts with mouse CD117, also known as c-Kit receptor, Steel factor receptor and stem cell factor receptor
• A member of the tyrosine kinase receptor family, this 145 kDa molecule is expressed by a majority of hematopoietic progenitor cells characterized in the mouse bone marrow as a small subset of cells positive for Sca-1 and Thy1 (Thy1^lo) and negative for lineage markers
• The interaction of the mouse c-kit receptor and steel factor promotes the proliferation and differentiation of hematopoietic progenitor cells
• CD117 is also expressed by mast cells and plays a role in signaling and activation of these cells
• ACK2 has been reported to be a blocking antibody
• Applications Reported: The ACK2 antibody has been reported for use in flow cytometric analysis
• It has also been reported for use in functional assays
• (Fluorochrome-conjugated ACK2 is recommended for use in flow cytometric analysis.)
• Applications Tested: The ACK2 antibody has been tested by flow cytometric analysis of mouse bone marrow cells
• This can be used at less than or equal to 0.125 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Endotoxin: Less than 0
• KIT (c-KIT) is a proto-oncogene and a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor)
• KIT was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit
• KIT together with its ligand regulates growth and activation of a variety of hemopoietic and non-hemopoietic cells
• Mutations in KIT are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism
• Recently, deregulation of the KIT receptor TK by the prevalent activation loop mutation D816V has served as a focal point in therapeutic strategies aimed at curbing neoplastic mast cell growth
• c-Kit is expressed in hematopoietic stem cells, germ cells, mast cells and gastrointestinal tract cajal cells
• Upon binding of its ligand stem cell factor (SCF), c-kit dimerizes, resulting in receptor activation and autophosphorylation of various tyrosine residues including tyrosine 703 located on the cytoplasmic domain of the receptor
• This modification allows docking of Grb2 and activation of the Ras/ERK signaling pathway
• SCF/c-kit can activate multiple downstream signaling pathways including PI3K, PLC-gamma and JAK/STAT
• c-kit receptor activation is essential for hematopoiesis, stem cell maintenance and gametogenesis.